MatTek Corporation, 200 Homer Avenue, Ashland, MA, 01721, USA.
In Vitro Cell Dev Biol Anim. 2024 Jun;60(6):569-582. doi: 10.1007/s11626-024-00907-1. Epub 2024 Jul 12.
Personal lubricants intended for local or systemic delivery via the vaginal route can induce vaginal irritation, damage the vaginal epithelial barrier which can enhance microbial entry, induce inflammation, and alter the microbiome of the vaginal ecosystem. Therefore, manufacturers of personal lubricants and medical devices are required to show biocompatibility and safety assessment data to support regulatory decision-making within a specified context of use. Furthermore, due to ethical concerns and the introduction of the 7th amendment of the European Council Directive which bans animal testing for cosmetic ingredients and products coupled with the Food and Drug Administration modernization Act 2.0 guidelines, there is a wave of drive to develop alternative test methods to predict human responses to chemical or formulation exposure. In this framework, there is a potential to use three-dimensional organotypic human vaginal-ectocervical tissue models as a screening tool to predict the vaginal irritation potential of personal lubricants and medicaments. To be physiologically relevant, the in vitro tissue models need to be reconstructed using primary epithelial cells of the specific organ or tissue and produce organ-like structure and functionality that recapitulate the in vivo-like responses. Through the years, progress has been made and vaginal tissue models are manufactured under controlled conditions with a specified performance criterion, which leads to a high level of reproducibility and reliability. The utility of vaginal tissue models has been accelerated in the last 20 years with an expanded portfolio of applications ranging from toxicity, inflammation, infection to drug safety, and efficacy studies. This article provides an overview of the state of the art of diversified applications of reconstructed vaginal tissue models and highlights their utility as a tool to predict vaginal irritation potential of feminine care products.
个人润滑剂,无论是局部使用还是通过阴道途径全身给药,都可能引起阴道刺激,破坏阴道上皮屏障,从而增加微生物进入的风险,引发炎症,并改变阴道生态系统的微生物群。因此,个人润滑剂和医疗器械的制造商需要提供生物相容性和安全性评估数据,以支持在特定使用范围内的监管决策。此外,由于伦理问题,以及欧洲理事会指令第 7 修正案的出台,该修正案禁止对化妆品成分和产品进行动物测试,再加上食品和药物管理局现代化法案 2.0 的指导方针,人们纷纷致力于开发替代测试方法,以预测人体对化学物质或制剂暴露的反应。在这一框架内,有可能利用三维器官型人阴道-宫颈组织模型作为筛选工具,预测个人润滑剂和药物的阴道刺激性。为了具有生理相关性,体外组织模型需要使用特定器官或组织的原代上皮细胞进行重建,并产生类似于器官的结构和功能,以再现类似体内的反应。多年来,已经取得了进展,并在特定的性能标准下,在受控条件下制造阴道组织模型,从而实现了高度的可重复性和可靠性。在过去的 20 年里,阴道组织模型的应用得到了加速,应用范围从毒性、炎症、感染到药物安全性和功效研究等方面不断扩大。本文概述了重建阴道组织模型的多样化应用的最新进展,并强调了其作为预测女性护理产品阴道刺激性潜力的工具的实用性。